Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.58 |
| ▸ | TUBB | P07437 | 3/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.58 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.58 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.58 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.58 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.58 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.58 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.58 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.58 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL412289 | 0.87 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2TUBB4ATUBBTUBA3C | |
| Hydrochloric Acid SCHEMBL412059 | 0.86 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2TUBB4ATUBBTUBA3C | |
| SCHEMBL10189641 | 0.86 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TUBB4ATUBBTUBA3C | |
| SCHEMBL10241213 | 0.82 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2TUBB4ATUBBTUBA3C | |
| SCHEMBL412245 | 0.82 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL17225918 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2TUBB4ATUBBTUBA3C | |
| SCHEMBL411117 | 0.80 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL28015514 | 0.80 | TUBB4A (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL411520 | 0.80 | TUBB4A (0.59) | ALDH1A1SMN1; SMN2TUBB4ATUBBTUBA3C | |
| SCHEMBL410296 | 0.79 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175022-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-12-19 | — | — | US | disclosed |
| US-8501790-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-1919881-B1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| EP-1919881-B1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2012-01-26 | — | — | US | disclosed |
| US-20100279410-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2010-11-04 | — | — | US | disclosed |
| US-7781462-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781462-B2 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | SYNTA PHARMACEUTICALS CORP. | 2010-04-15 | — | — | US | disclosed |
| EP-2059250-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | Synta Pharmaceuticals Corporation (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1919881-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | Synta Pharmaceuticals Corporation (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2008033449-A2 | COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | SYNTA PHARMACEUTICALS CORP. | 2007-10-11 | — | — | US | disclosed |
| WO-2007014198-A1 | 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238699-A1 | Compounds for the treatment of proliferative disorders | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885SMN1; SMN2 3188/4885TUBB4A 18/4885 |
| US-20120022118-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885SMN1; SMN2 3188/4885TUBB4A 18/4885 |
| US-20100093670-A1 | Compounds for the treatment of angiogenesis | FLT4, FLT1, TEK | ALDH1A1 414/4885SMN1; SMN2 4855/4885TUBB4A 56/4885 |
| US-20130338112-A1 | COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | RB1, MKI67, MAPRE1 | ALDH1A1 1872/4885SMN1; SMN2 3188/4885TUBB4A 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.